Age: 41.0
Sex: M
Vaccine: COVID19, UNK
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: Rebound in symptoms and positive at home rapid. Covid test one week after stopping Paxlovid. Daily at home tests may 1- 14. May 2 symptoms but negative. May 3 symptoms and positive.; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Rebound in symptoms and positive at home rapid. Covid test one week after stopping Paxlovid. Daily at home tests may 1- 14. May 2 symptoms but negative. May 3 symptoms and positive.) in a 41-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment.    The patient's past medical history included Depression. Concurrent medical conditions included Allergy and Drug allergy (Unknown historical drug). Concomitant products included BUPROPION HYDROCHLORIDE (WELLBUTRIN), ESCITALOPRAM OXALATE (LEXAPRO) and CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) for an unknown indication.   On 15-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-May-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) at an unspecified dose. On 03-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (Rebound in symptoms and positive at home rapid. Covid test one week after stopping Paxlovid. Daily at home tests may 1- 14. May 2 symptoms but negative. May 3 symptoms and positive.). At the time of the report, COVID-19 (Rebound in symptoms and positive at home rapid. Covid test one week after stopping Paxlovid. Daily at home tests may 1- 14. May 2 symptoms but negative. May 3 symptoms and positive.) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 01-May-2022, SARS-CoV-2 test: results not reported Results not reported. On 02-May-2022, SARS-CoV-2 test: negative (Negative) symptoms but negative. On 03-May-2022, SARS-CoV-2 test: positive (Positive) symptoms and positive. On 04-May-2022, SARS-CoV-2 test: results not reported Results not reported. On 05-May-2022, SARS-CoV-2 test: results not reported Results not reported. On 06-May-2022, SARS-CoV-2 test: negative (Negative) Negative and vastly improved symptoms. On 07-May-2022, SARS-CoV-2 test: negative (Negative) Negative. On 08-May-2022, SARS-CoV-2 test: negative (Negative) Negative. On 09-May-2022, SARS-CoV-2 test: negative (Negative) Negative. On 10-May-2022, SARS-CoV-2 test: negative (Negative) Negative. On 11-May-2022, SARS-CoV-2 test: negative (Negative) Negative. On 12-May-2022, SARS-CoV-2 test: negative (Negative) Negative. On 13-May-2022, SARS-CoV-2 test: negative (Negative) Negative. On 14-May-2022, SARS-CoV-2 test: positive (Positive) Positive with symptoms.         Patient had rebound in symptoms and was tested positive at home rapid Covid test one week after stopping Paxlovid.  Patient had home tests for COVID-19 from 01-May-2022 to 14-May-2022 daily.  Patient began Paxlovid within hours of positive test on 03-May-2022. No treatment medications were provided.  Company Comment: This spontaneous case concerns a 41 year old male patient with no relevant medical history reported , who experienced Non-serious , unexpected. AESI of Covid 19 which occurred 6 months , 18 days post vaccination with the 3rd dose of mRNA-1273 vaccine . The details regarding the dose 1 and dose 2 Covid 19 vaccine of this patient was not reported. This patient did daily home test using  Home Rapid Covid test  starting May 2 with reported  negative results  but he was already symptomatic while on May 3 it was positive and he still have symptoms , May 4-5  results was not reported and from may 6 it was negative and symptoms have greatly improved , May 7 -  May 13 he was negative  however on May 14 he had recurrence of symptoms and positive for the Home rapid Covid test. This patient also took the Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment form May 3-7, 2022.   Other treatment information , results of other  laboratories/diagnostic procedures like the RT-PCR or viral culture test etc . were not reported and there was no report if any medical consult was done. Outcome of the event was reported as unknown. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.; Sender's Comments: This spontaneous case concerns a 41 year old male patient with no relevant medical history reported , who experienced Non-serious , unexpected. AESI of Covid 19 which occurred 6 months , 18 days post vaccination with the 3rd dose of mRNA-1273 vaccine . The details regarding the dose 1 and dose 2 Covid 19 vaccine of this patient was not reported. This patient did daily home test using  Home Rapid Covid test  starting May 2 with reported  negative results  but he was already symptomatic while on May 3 it was positive and he still have symptoms , May 4-5  results was not reported and from May 6 it was negative and symptoms have greatly improved , May 7 -  May 13 he was negative  however on May 14 he had recurrence of symptoms and positive for the Home rapid Covid test. This patient also took the Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment form May 3-7, 2022.   Other treatment information , results of other  laboratories/diagnostic procedures like the RT-PCR or viral culture test etc . were not reported and there was no report if any medical consult was done. Outcome of the event was reported as unknown. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.